Executive Director, Expertise Kinase Platforrm, CPC
Novartis Pharma AG, Postfach, CH-4002 Basel, SWITZERLAND
Doriano Fabbro received his PhD in cell biology and biochemistry at the Biocenter Basel, Switzerland, for the studies on the mechanisms of activation of PKC. In 1991, he joined the Oncology Research group of Ciba-Geigy Basel where he contributed to the discovery of Midostaurin as well as Glivec. Following the merger of Ciba-Geigy with Sandoz to form Novartis in 1996, he was promoted to Executive Director in Oncology Research directing drug discovery efforts focusing on ATP-dependent enzymes (protein kinases and ATPases) as well as other small molecular weight approaches. In 2006, he was instrumental for the establishment of the NIBR Expertise Platform Kinases where he serves as Head of the Kinase Biology until today.
Dr. Fabbro is a member of various professional societies and several journal editorial boards and has contributed to the discovery and development of various protein kinase inhibitors for the treatment of cancer including inhibitors including compounds that reached full development/registration like RAD001 (Everolimus, Afinitor, launched), STI571 (Imatinib, Glivec, launched), AMN107 (Nilotinib, Tasigna, launched) and PKC412 (Midostaurin, Ph III). He has written patents and numerous publications in the area of protein kinase regulation, structure, screening and drug discovery.
Drug resistance mechanisms for kinase inhibitors
Protein kinases escape resistance by either mutating key residues in their kinase domain or by pathway reactivation. Understanding the mechanisms of resistance to kinase inhibition will allow the development of appropriate strategies to override the various types of resistances.